Disease · MONDO_0005235

smoldering plasma cell myeloma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. smoldering plasma cell myeloma. Diseases, record MONDO_0005235. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005235

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: smoldering plasma cell myeloma; Open Targets
Open Targets ID: MONDO_0005235; Open Targets
Other names: asymptomatic myeloma, asymptomatic plasma cell myeloma, smoldering Multiple myeloma/plasma cell myeloma, smoldering multiple myeloma, smoldering myeloma, smouldering Multiple myeloma/plasma cell myeloma, smouldering multiple myeloma, smouldering myeloma; Open Targets
Disease Ontology: DOID:9551; Disease Ontology
NCI Thesaurus: C7149; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 7 of its 22 drugs, from ClinicalTrials.gov; Open Targets

Drugs22

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
DARATUMUMAB	CHEMBL1743007	Antibody	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
ISATUXIMAB	CHEMBL3545131	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
THALIDOMIDE	CHEMBL468	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ZOLEDRONIC ACID	CHEMBL4303669	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
HYALURONIDASE (HUMAN RECOMBINANT)	CHEMBL1201718	Enzyme	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BORTEZOMIB	CHEMBL325041	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
LEFLUNOMIDE	CHEMBL960	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CARFILZOMIB	CHEMBL451887	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 22

See all 22 drugs

Targets69

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CRBN	CRL4(CRBN) E3 ubiquitin ligase	4	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 3	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	4	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 3	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	4	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 3	https://conductscience.org/library/genes/1642	Drugs and targets
RBX1	CRL4(CRBN) E3 ubiquitin ligase	4	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 3	https://conductscience.org/library/genes/9978	Drugs and targets
ADRM1	26S proteasome	3	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/11047	Drugs and targets
PSMA1	26S proteasome	3	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5682	Drugs and targets
PSMA2	26S proteasome	3	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5683	Drugs and targets
PSMA3	26S proteasome	3	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5684	Drugs and targets
PSMA4	26S proteasome	3	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5685	Drugs and targets
PSMA5	26S proteasome	3	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5686	Drugs and targets

1 to 10 of 69

See all 69 targets

Trials27

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03301220	A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma	Phase 3	390	2025-12-23	Smoldering Multiple Myeloma	DARATUMUMAB, HYALURONIDASE (HUMAN RECOMBINANT)	Its record names the disease	ClinicalTrials.gov
NCT01484275	A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma	Phase 2	85	2020-01-27	High-risk Smoldering Multiple Myeloma	SILTUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00083382	Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide	Phase 2	83	2015-06-24	Multiple Myeloma	PAMIDRONIC ACID, THALIDOMIDE, ZOLEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00432458	Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma	Phase 3	68	2012-07-04	Multiple Myeloma and Plasma Cell Neoplasm	THALIDOMIDE, ZOLEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01572480	Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma	Phase 2	55	2022-09-13	Multiple Myeloma	CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT01441973	Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma	Phase 2	41	2016-01-29	Smoldering Multiple Myeloma	ELOTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00983346	Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients	Phase 2	17	2015-11-30	Cancer, Myeloma, Multiple Myeloma	BORTEZOMIB	Its record names the disease	ClinicalTrials.gov
NCT05288062	Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma	Phase 2	17	2025-08-20	Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma	DEXAMETHASONE, LENALIDOMIDE, POMALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT04270409	Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma	Phase 3	337		Plasma Cell Myeloma	DEXAMETHASONE, ISATUXIMAB, LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT03937635	Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma	Phase 3	288		Smoldering Plasma Cell Myeloma	DARATUMUMAB, DEXAMETHASONE, LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 27

See all 27 trials

Comparisons in its trials11

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm A: Active Monitoring (ACTM) vs Arm B: Daratumumab SC: deaths from any cause	26 of 196	15 of 194	390	NCT03301220	Trial comparisons
Arm A: Active Monitoring (ACTM) vs Arm B: Daratumumab SC: serious adverse events	38 of 196	56 of 193	389	NCT03301220	Trial comparisons
Siltuximab vs Placebo: deaths from any cause	3 of 43	4 of 42	85	NCT01484275	Trial comparisons
Siltuximab vs Placebo: serious adverse events	13 of 43	13 of 42	85	NCT01484275	Trial comparisons
Arm I: Thal/ZLD vs Arm II: ZLD: Number of Participants With Severe (Grade 3, 4 or 5) Adverse Events	17 of 35	13 of 33	68	NCT00432458	Trial comparisons
Arm I: Thal/ZLD vs Arm II: ZLD: Number of Participants With a Confirmed Response (Complete Response [CR], Very Good Partial Response [VGPR] or Partial Response [PR]) on Two Consecutive Evaluations at Least 2 Weeks Apart in the First 12 Months of Treatment	13 of 35	0 of 33	68	NCT00432458	Trial comparisons
Arm I: Thal/ZLD vs Arm II: ZLD: 12-month Progression-free Survival (PFS)	30 of 35	18 of 33	68	NCT00432458	Trial comparisons
Arm I: Thal/ZLD vs Arm II: ZLD: serious adverse events	3 of 35	1 of 33	68	NCT00432458	Trial comparisons
Elotuzumab(E) : 10 mg/kg/Dose vs Elotuzumab(E) : 20 mg/kg/Dose: serious adverse events	7 of 16	8 of 15	31	NCT01441973	Trial comparisons
Cohort B (Lenalidomide, Dexamethasone) vs Cohort C (Lenalidomide, Dexamethasone, Pomalidomide): deaths from any cause	0 of 5	0 of 11	16	NCT05288062	Trial comparisons

1 to 10 of 11

See all 11 comparisons in its trials

Papers from its trials13

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42747040	DERIVED	1	PubMed
39652826	DERIVED	1	PubMed
39652675	DERIVED	1	PubMed
38652812	DERIVED	1	PubMed
34529025	DERIVED	1	PubMed
33474705	DERIVED	1	PubMed
32024950	DERIVED	1	PubMed
30890552	DERIVED	1	PubMed
30128502	DERIVED	1	PubMed
26690712	DERIVED	1	PubMed

1 to 10 of 13

See all 13 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005235

GET https://conductscience.org/api/diseases/v1/MONDO_0005235/drugs?page=2

API reference For AI assistants